Rivaroxaban is an oral, direct Factor Xa inhibitor that targets free and clot-bound Factor Xa
and Factor Xa in the prothrombinase complex. It is absorbed rapidly, with maximum plasma …

Clinicians and patients around the world have been intrigued by the concept of developing
an oral anticoagulant with a broad therapeutic window and few drug and dietary interactions …

Background Left ventricular thrombus (LVT) is not uncommon and pose a risk of systemic
embolism, which can be mitigated by adequate anticoagulation. Direct oral anticoagulants …

Direct oral anticoagulants (DOAC) have shown an upward prescribing trend in recent years
due to favorable pharmacokinetics and pharmacodynamics without requirement for routine …

Unlike traditional anticoagulants, the more recently developed agents rivaroxaban,
dabigatran and apixaban target specific factors in the coagulation cascade to attenuate …

Background: The oral anticoagulant rivaroxaban is recommended for venous
thromboembolic prophylaxis following lower limb arthroplasty. Concerns regarding high …

Ischemic stroke represents one of the leading causes of death and disability in both the
United States and abroad, particularly for patients with prior ischemic stroke or transient …

Background: Over the last ten years, a new class of drugs, known as the direct-acting oral
anticoagulants (DOACs), have emerged at the forefront of anticoagulation therapy. Like the …

Newer oral anticoagulants offer several advantages over traditional agents (eg warfarin), but
they are still associated with a bleeding risk and currently there is no validated reversal …

Emerging epidemic-prone diseases have introduced numerous health and economic
challenges in recent years. Given current knowledge of COVID-19, herd immunity through …